Tony W Ho, Executive VP of CRISPR Therapeutics AG, recently acquired 1,748 shares of the company. The buys took place at prices ranging from $0.00 to $114.65 per share, on March 05, 2021. Ho now owns 35,862 shares of the company. Ho operates out of Cambridge, MA. Some additional info was provided as follows:
On March 5, 2019, the reporting person was granted 10,000 restricted stock units. On March 5, 2021, 3,333 restricted stock units vested.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Includes 150 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!
Other recent filings from the company include the following:
CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
Initial statement of beneficial ownership of securities - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021